Fas/FasL signaling is critical for the survival of exhausted antigen-specific CD8+ T cells during tumor immune response-Reference-Cited by-同舟云学术

Fas/FasL signaling is critical for the survival of exhausted antigen-specific CD8+ T cells during tumor immune response

Published:2019-03 Issue: Volume:107 Page:97-105
ISSN:0161-5890
Container-title:Molecular Immunology
language:en
Short-container-title:Molecular Immunology

Author:

Yajima Toshiki,Hoshino Kouki^ORCID,Muranushi Ryo,Mogi Akira,Onozato Ryoichi^ORCID,Yamaki Ei,Kosaka Takayuki,Tanaka Shigebumi,Shirabe Ken,Yoshikai Yasunobu,Kuwano Hiroyuki

Funder

Grant-in-Aid for Scientific Research, the Japanese Ministry of Education, Culture, Sports, Science and Technology

Publisher

Elsevier BV

Subject

Molecular Biology,Immunology

Reference44 articles.

1. Immunological memory and protective immunity: understanding their relation;Ahmed;Science,1996

2. Fas ligand mediates activation-induced cell death in human T lymphocytes;Alderson;J. Exp. Med.,1995

3. Death receptors: signaling and modulation;Ashkenazi;Science,1998

4. Restoring function in exhausted CD8 T cells during chronic viral infection;Barber;Nature,2006

5. Histone deacetylase inhibitors prevent activation-induced cell death and promote anti-tumor immunity;Cao;Oncogene,2015

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic Value of Fas/Fas Ligand Expression on Circulating Tumor Cells (CTCs) and Immune Cells in the Peripheral Blood of Patients with Metastatic Breast Cancer;Cancers;2024-08-23

2. Circulating immune-related proteins associated with immune checkpoint inhibitor efficacy in patients with pancreatic ductal adenocarcinoma;ESMO Open;2024-06

3. Destabilizing the genome as a therapeutic strategy to enhance response to immune checkpoint blockade: a systematic review of clinical trials evidence from solid and hematological tumors;Frontiers in Pharmacology;2024-01-09

4. T Cell Subsets and Immune Homeostasis;Methods in Molecular Biology;2024

5. Exhausted T cells hijacking the cancer-immunity cycle: Assets and liabilities;Frontiers in Immunology;2023-04-14